Work

First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps3157

Authors: R. Donald Harvey, Gerald Steven Falchook, Abdul Rafeh Naqash, Joseph W. Kim, Afshin Dowlati, Yvan Le Bruchec, Isabelle Coudert, Annette L. Ervin-Haynes, David Sommerhalder

Institutions: Winship Cancer Institute, HealthONE, University of Oklahoma Medical Center, OU Health Stephenson Cancer Center, University of Oklahoma, Yale Cancer Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Adc Therapeutics (Switzerland), Celgene (United States), Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center Shreveport

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286295512

Cites:

Cited by: 1

Related to: 10